Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia

Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia Key PointsQuestionWhat are the risks of hypophosphatemia following iron replacement with iron isomaltoside 1000 (now called ferric derisomaltose) vs ferric carboxymaltose? FindingsIn 2 randomized trials of 245 total patients (trial A: n = 123; trial B: n = 122) with iron-deficiency anemia, who were intolerant to or unresponsive to oral iron, the incidence of hypophosphatemia with use of iron isomaltoside, compared with ferric carboxymaltose, was 7.9% vs 75.0% in trial A and 8.1% vs 73.7% in trial B over 35 days; both differences were statistically significant. MeaningIron isomaltoside, compared with ferric carboxymaltose, resulted in lower incidence of hypophosphatemia, but further research is needed to determine the clinical importance of these findings. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia

Loading next page...
 
/lp/american-medical-association/effects-of-iron-isomaltoside-vs-ferric-carboxymaltose-on-GPmI0K07vX
Publisher
American Medical Association
Copyright
Copyright 2020 American Medical Association. All Rights Reserved.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2019.22450
Publisher site
See Article on Publisher Site

Abstract

Key PointsQuestionWhat are the risks of hypophosphatemia following iron replacement with iron isomaltoside 1000 (now called ferric derisomaltose) vs ferric carboxymaltose? FindingsIn 2 randomized trials of 245 total patients (trial A: n = 123; trial B: n = 122) with iron-deficiency anemia, who were intolerant to or unresponsive to oral iron, the incidence of hypophosphatemia with use of iron isomaltoside, compared with ferric carboxymaltose, was 7.9% vs 75.0% in trial A and 8.1% vs 73.7% in trial B over 35 days; both differences were statistically significant. MeaningIron isomaltoside, compared with ferric carboxymaltose, resulted in lower incidence of hypophosphatemia, but further research is needed to determine the clinical importance of these findings.

Journal

JAMAAmerican Medical Association

Published: Feb 4, 2020

References